Researchers performed a secondary analysis Norway-based randomized sigmoidoscopy screening data. About 20,552 underwent screenings, while 78,126 did not undergo sigmoidoscopy screening. Researchers compared 163 patients with CRC mortality and all-cause mortality who were screened then diagnosed with CRC to a group of 1,740 unscreened patients diagnosed with CRC .
Here’s what you should know:
1. Forty-three individuals in the screened interval cancer group died from CRC. About 525 in the control group died from CRC.
2. Rectosigmoid cancer mortality and all-cause mortality did not differ between the screened interval cancer group and the controls.
3. Researchers concluded, “In this randomized sigmoidoscopy screening trial, mortality did not differ significantly between individuals with interval CRCs and unscreened patients with clinically detected CRCs.”
More articles on gastroenterology:
Beaumont Health opening 2 outpatient campuses with surgery centers — 6 insights
4 things to know about Regent Surgical Health’s CEO Chris Bishop
3 strategies for ASC accounts receivable management
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.